The first among Indian pharmaceutical companies to realise and embrace the importance of innovation, we invest 6–8% of global revenues annually into Research and Development (R&D). With a team of over 2,700 R&D personnel with strong intellectual capabilities in formulations, process chemistry, and analytical development, our strength lies in developing generics and technologically complex products. We specialize in differentiated products including liposomal drugs, inhalers, lyophilized injections, nasal sprays, and controlled-release dosage forms, showcasing our strong focus on innovation.
Recent Posts
- Press Release Sun Pharma reports Q2 & half year results for FY27
- SPIL Q2FY27 Financial Results
- At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
- Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma
- Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
Recent Comments